This is the molecule page. Ozempic, Wegovy, and Rybelsus are all the same drug — semaglutide — so the question "when does semaglutide go generic?" is really one patent story with three brand endings.
Direct answer: No FDA-approved generic semaglutide exists in the United States in 2026. The reason is a single, extended compound patent: Novo Nordisk's patent on the semaglutide molecule was given a term extension that pushes it to December 2031, and patent analysts project the first licensed US generic around 2032. A generic maker (Apotex) already has a tentative FDA approval as of April 2026 — meaning the product passed FDA review but legally can't launch until the patents clear. Canada, by contrast, got real generic semaglutide in 2026 because Novo let a patent lapse there. And the cheap "compounded semaglutide" flooding telehealth ads is not a generic — a distinction the FDA hardened with an April 2026 restriction. Here's the full timeline.
What "generic semaglutide" actually means
A generic is an FDA-approved copy of a brand drug that's proven bioequivalent — same active ingredient, same strength, same effect. Semaglutide is a peptide GLP-1 receptor agonist, and a generic semaglutide injection would be interchangeable with Ozempic (and usable off-label for everything Ozempic is used for). The brands differ only by dose and indication: Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight management. So a single generic semaglutide approval ripples across all three franchises — which is exactly why the patents are defended so aggressively.
The patent cliff: one molecule, several walls
| Milestone | What it covers | Timing |
|---|---|---|
| '122 compound patent | Early compound claim | 2026 |
| '343 compound patent (US 8,129,343) | Semaglutide molecule, with term extension | December 2031 |
| '462 method-of-use patent | Type 2 diabetes use | June 2033 |
| Estimated first US generic (injection) | First licensed launch | ~2032 |
| Earliest estimated generic Rybelsus | Oral tablet | March 15, 2033 |
| Rybelsus '248 SNAC formulation patent | Oral absorption formulation | 2039 |
| Wegovy / Rybelsus broader portfolio | Surrounding claims | ~2040 |
The single most important date is December 2031 — the extended compound patent. A 2023 challenge by Mylan against that patent failed, which locked the wall in place. The injectable generic should arrive first (~2032); the oral generic (Rybelsus) lags because the SNAC formulation patents run to 2039. So "semaglutide goes generic" won't be one event — it'll be the injection around 2032 and the tablet years later.
First-filer generics: approved on paper, blocked in practice
Generic makers haven't been waiting around. The race is already over in the FDA's labs — it's the courts and patents holding the launch.
| Generic maker | Status | Notes |
|---|---|---|
| Apotex (with Orbicular) | First tentative FDA approval, April 2026 | Cleared FDA review; can't launch until patents clear |
| Mylan | Settled fall 2024 (confidential terms) | Its 2023 IPR against the '343 patent failed |
| Dr. Reddy's | Settled fall 2024 (confidential terms) | Some method-of-use litigation pending |
| Sun Pharmaceuticals | Settled fall 2024 (confidential terms) | Litigation partly pending |
In fall 2024, Novo Nordisk settled patent suits with this group on confidential terms, so the public doesn't know the exact licensed entry dates — only that Markman Advisors reads the overall picture as generic entry around 2032. The Apotex tentative approval in April 2026 is the clearest signal yet that the supply side is ready and only the legal clock is left.
Canada already has it — here's why, and why you can't import it
In April 2026, Canada became the first G7 country to approve a generic semaglutide. Apotex's Apo-Semaglutide Injection (a generic of Ozempic, with 2 mg and 4 mg pens) began shipping May 20, 2026, followed by a Dr. Reddy's version, at roughly one-third of brand pricing. The cause was procedural, not scientific: Novo Nordisk missed a Canadian patent maintenance fee, and a lapsed Canadian patent can't be revived. US patents remain intact to ~2032, so there's no equivalent opening here.
Importing the Canadian generic is not a legal workaround for US patients. Personal importation of Ozempic-class drugs generally isn't permitted, Canadian pharmacies require a Canadian-licensed prescriber, and the cross-border GLP-1 market draws counterfeits.
Why compounded semaglutide is not a generic — and what April 2026 changed
This is the biggest source of confusion. "Compounded semaglutide" is custom-mixed by a pharmacy; it is not FDA-approved and not bioequivalence-tested.
| FDA-approved generic | Compounded semaglutide | |
|---|---|---|
| FDA approval | Yes | No |
| Bioequivalence proven | Yes | No |
| Legal under shortage only | No (permanent) | Was tied to the shortage |
| Available in US now | No | Restricted and shrinking |
Compounding was legal during the 2022-2024 shortage. Then the FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, ending the broad exception. On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list entirely — closing the door even if a future shortage returns — with public comment open through June 29, 2026. The agency cited hundreds of adverse-event reports tied to compounded GLP-1s. Doctor-supervised compounding through a licensed US pharmacy remains a regulated route for now, but it's not a generic.
Want the generic price without the wait? Yücca telehealth — online evaluation, doctor-prescribed compounded Semaglutide+ or Tirzepatide+ filled by a licensed US pharmacy, from $146/month. (Partner link: we may earn a commission, at no extra cost to you.)
"Generic price" routes that exist today
No generic, but real ways to pay less than the ~$1,000-1,300 list price:
| Route | What it is | Cash price |
|---|---|---|
| Oral Wegovy pill (starter dose) | Once-daily semaglutide tablet | $149/month |
| NovoCare self-pay injectable | Direct cash from Novo Nordisk | ~$349-499/month |
| Manufacturer savings card | Commercial-insurance copay help | As low as $0-25/month |
| Doctor-supervised compounded semaglutide | Licensed US pharmacy via telehealth | From ~$146/month |
Then dig into the specific brand: Ozempic generic for the diabetes injection, Wegovy generic for the weight-loss pill and cash routes, and Rybelsus generic for the oral tablet's longer patents. For prices across the whole class, see the cheapest GLP-1 roundup and the brand savings guides (Ozempic, Wegovy, Rybelsus).
Frequently asked questions
When will generic semaglutide be available in the US? The injectable generic is projected around 2032, after the December 2031 compound patent expires. Generic oral semaglutide (Rybelsus) is later still, with formulation patents to 2039.
Has the FDA approved any generic semaglutide? Only tentatively. Apotex received the first tentative FDA approval in April 2026, which confirms the product passed review but does not allow a launch while patents stand.
Is compounded semaglutide a generic? No. It isn't FDA-approved or bioequivalence-tested, and the FDA is moving to end bulk compounding now that the shortage is resolved.
Why does Canada have generic semaglutide before the US? Novo Nordisk missed a patent maintenance fee in Canada, and a lapsed Canadian patent can't be revived. US patents run to roughly 2032.
Is semaglutide a biologic that needs a biosimilar instead of a generic? Semaglutide is a synthetic peptide, so it follows the small-molecule generic (ANDA) pathway, not the biosimilar pathway — which is why "generic semaglutide" is the correct framing.
Will generic semaglutide be cheap right away? Not necessarily on day one. Prices usually fall meaningfully once multiple generic makers compete, which can take time after the first launch.
Last reviewed: June 13, 2026
Sources
- What is the patent landscape for Novo Nordisk's semaglutide products? — Markman Advisors
- Apotex Wins First Tentative FDA Approval for Generic Semaglutide Injection — Prism News
- Generic semaglutide to hit Canadian pharmacies this week at lower cost — Global News
- Novo Nordisk missed a patent deadline in Canada, opening the door to generic GLP-1s — eMarketer
- FDA Moves to Permanently Close the Door on Compounded GLP-1s — Pharmacy Times
- When do the patents on RYBELSUS expire? — DrugPatentWatch
- Canadian pharmacy Ozempic: Cost, availability & more — SingleCare
